Fully funded by 
Content independently selected
5-year survival higher for liver cancer due to nonalcoholic fatty liver disease.
Surveillance is warranted.
Eighth International Forum for Liver MRI yields 20 consensus statements.
Consider PTR in these patients, but factor age and primary tumor site, size, and differentiation into the decision.
HCC risk factors are recognizable and should raise flags.
The presence of lymph node metastasis should not be a contraindication for resection.
TACE-RFA should be preferred over TACE for recurrent tumors of 5 cm or less.
Careful monitoring is warranted for older patients with low albumin.
Nearly doubled OS vs frontline sorafenib alone.
A previous, retrospective analysis had suggested that neoadjuvant 3D conformal radiotherapy may be effective in HCC with PVTT. This randomized trial provides direct evidence.
An interval of more than 2 years between breast cancer surgery and development of liver metastasis bodes well, among other factors.
There is no currently recommended postop treatment for HCC with MVI.
A consensus report from the Miami Liver Proton Therapy Conference.
Prior studies have returned mixed results.
An on-site interview with Åsmund Avdem Fretland, MD.
Evidence from the Scottish Primary Care Clinical Informatics Unit (PCCIU) database and the UK Biobank.
The first biomarker-driven therapy approved for HCC.
